Back to journals
Academic Journal

Journal of Psychopharmacology

199 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 199 psychedelic papers Blossom tracks from Journal of Psychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Journal of Psychopharmacology carry?

Sourced

Tracked papers by publication year; 13 earlier papers published before 2012. Click a year for the running total.

28papers published in 2022

+27% vs 2021

141 published by 2022

Browse papers→

Don't read as the journal's total output: only the 199 of 199 tracked psychedelic papers from Journal of Psychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Journal of Psychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
82
Anxiety Disorders
72
Addiction & Substance Use
57
Safety & Risk Management
36
PTSD
30
Interpersonal Functioning & Social Connectedness
27
Neuroimaging & Brain Measures
23
Medicinal Chemistry & Drug Development
20
Other
180

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Journal of Psychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
77
MDMA
39
LSD
38
Ketamine
22
DMT
20
Ayahuasca
16
Mescaline
9
5-MeO-DMT
7
Other
11

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Journal of Psychopharmacology has 199 tracked papers indexed in Blossom (2000–2026) from 805 authors, most often covering Psilocybin, MDMA and LSD, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).

Published Papers

Paywallmeta

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression

This open-label clinical study (n=41) of inhaled DMT in healthy volunteers and people with treatment-resistant depression found short-term reductions in anxiety and longer-lasting improvements in life satisfaction and quality of life, especially in patients. The benefits were seen alongside psychological support, but the study had no placebo control.

Published
Journal
Journal of Psychopharmacology
Authors
Bolcont, R., Palhano-Fontes, F., Barros, H., Laborde, S., Amorim, D., Falchi-Carvalho, M., Galvão-Coelho, N., Wießner, I., Araujo, D. B.
Paywallindividual

Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test

This rat study examined whether blocking 5-HT2B receptors changes psilocybin’s effects in the forced swim test. In Wistar rats, a 5-HT2B blocker abolished psilocybin’s rapid and lasting antidepressant-like behaviour in the test, but did not affect the head-twitch response linked to psychedelic effects.

Published
Journal
Journal of Psychopharmacology
Authors
Seillier, L., Seillier, A., Zvolska, M. A., Šlamberová, R.
Open Accessmeta

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects

This systematic review (s=32) of healthy adult volunteers examined the pharmacokinetics of LSD, psilocybin, DMT, mescaline and 5-MeO-DMT. It found that LSD and psilocybin showed dose-related peak levels, while oral and intravenous DMT differed in ways that may matter clinically.

Published
Journal
Journal of Psychopharmacology
Authors
Hampsey, E., Martin, K., Kalfas, M., Benson, L., Wihlborg, S., Jelen, L., Young, A. H., Rucker, J.
Paywallmeta

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache

This observational study (n=11) of people with chronic cluster headache examined three doses of psilocybin (10 mg/70 kg) and found that self-reported sleep quality improved after treatment. Brain scans showed differences in microstructure and water diffusivity between patients and healthy controls, but psilocybin did not produce clear average changes in these measures.

Published
Journal
Journal of Psychopharmacology
Authors
Brendstrup-Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., McCulloch, D. E. W., Marstrand-Joergensen, M. R., Ulv Larsen, S. M., Johansen, A., Jensen, R. H., Knudsen, G. M., Madsen, M. K.
Open Accessindividual

Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat

This observational study (n=29) examined daily voice journals before and after a 5-MeO-DMT retreat and found that speech changed towards more cognitive and less social language, with altered voice quality. Baseline speech patterns also helped predict preparedness, emotional breakthrough and later well-being.

Published
Journal
Journal of Psychopharmacology
Authors
Kuc, J., McAlpine, R. G., Sellers, A., Blackburne, G., Lametti, D. R., Skipper, J. I.
Paywallindividual

5-HT1A receptor blockade potentiates the subjective effects of DMT

This double-blind, randomised, placebo-controlled within-subjects study (n=12) found that blocking the 5-HT1A receptor with 30 mg oral pindolol before a sub-hallucinogenic intravenous dose of DMT (7 mg/70kg) intensified the subjective effects with a moderate effect size, suggesting the 5-HT1A receptor contributes to how psychedelics produce their subjective effects.

Published
Journal
Journal of Psychopharmacology
Authors
Zahid, Z., Strassman, R. J., Qualls, C. R., Nayak, S. M.

Quick Facts

Papers Indexed
199
h-Index
143
Open Access
No
Publisher
SAGE Publications
Country
United Kingdom
Website
Visit